155 related articles for article (PubMed ID: 27555773)
1. Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.
Perepelyuk M; Maher C; Lakshmikuttyamma A; Shoyele SA
Int J Nanomedicine; 2016; 11():3533-44. PubMed ID: 27555773
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer.
Perepelyuk M; Sacko K; Thangavel K; Shoyele SA
Mol Pharm; 2018 Mar; 15(3):985-993. PubMed ID: 29432024
[TBL] [Abstract][Full Text] [Related]
3. Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates.
Sacko K; Thangavel K; Shoyele SA
Nanomaterials (Basel); 2019 Jul; 9(7):. PubMed ID: 31340494
[TBL] [Abstract][Full Text] [Related]
4. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.
Dai F; Zhang Y; Zhu X; Shan N; Chen Y
Target Oncol; 2012 Dec; 7(4):217-25. PubMed ID: 23179556
[TBL] [Abstract][Full Text] [Related]
5. Biofabrication of nano copper oxide and its aptamer bioconjugate for delivery of mRNA 29b to lung cancer cells.
Wu D; Wang W; He X; Jiang M; Lai C; Hu X; Xi J; Wang M
Mater Sci Eng C Mater Biol Appl; 2019 Apr; 97():827-832. PubMed ID: 30678973
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive cytosensing based on an aptamer modified nanobiosensor with a bioconjugate: Detection of human non-small-cell lung cancer cells.
Mir TA; Yoon JH; Gurudatt NG; Won MS; Shim YB
Biosens Bioelectron; 2015 Dec; 74():594-600. PubMed ID: 26190471
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells.
Wang H; Zhao X; Guo C; Ren D; Zhao Y; Xiao W; Jiao W
PLoS One; 2015; 10(9):e0139136. PubMed ID: 26406332
[TBL] [Abstract][Full Text] [Related]
8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
9. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.
Dai F; Zhang Y; Zhu X; Shan N; Chen Y
Gynecol Oncol; 2013 Nov; 131(2):451-9. PubMed ID: 23933187
[TBL] [Abstract][Full Text] [Related]
10. Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer.
Kurosaki T; Higuchi N; Kawakami S; Higuchi Y; Nakamura T; Kitahara T; Hashida M; Sasaki H
Gene; 2012 Jan; 491(2):205-9. PubMed ID: 22001405
[TBL] [Abstract][Full Text] [Related]
11. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional silver nanocluster-hybrid oligonucleotide vehicle for cell imaging and microRNA-targeted gene silencing.
Chen HY; Albert K; Wen CC; Hsieh PY; Chen SY; Huang NC; Lo SC; Chen JK; Hsu HY
Colloids Surf B Biointerfaces; 2017 Apr; 152():423-431. PubMed ID: 28171795
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
[TBL] [Abstract][Full Text] [Related]
14. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Biochem Biophys Res Commun; 2012 Feb; 418(3):547-52. PubMed ID: 22290228
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-495 mimics delivery inhibits lung tumor progression.
Ai C; Jiang R; Fu L; Chen Y
Tumour Biol; 2015 Feb; 36(2):729-35. PubMed ID: 25286762
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
19. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
Tan M; Wu J; Cai Y
Biochem Biophys Res Commun; 2013 Sep; 438(4):673-9. PubMed ID: 23939044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
